OBJECTIVE: To report our experience on the safety and tolerability of moxifloxacin for treating children affected by pulmonary TB. STUDY DESIGN: Children receiving a moxifloxacin-containing anti-TB regimen were included in the study. Their medical records were revised at the end of follow-up. METHODS: We describe nine children treated with moxifloxacin for pulmonary TB at Regina Margherita Children's Hospital (Turin, Italy) between 2007 and 2012. Moxifloxacin was administered orally at 10 mg/kg/day once daily (maximum dose = 400 mg/day) following World Health Organization indications. During treatment, patients were systematically assessed for the development of side effects. RESULTS: Eight children were considered cured at the end of treatment; one child was lost to follow-up after 3 months of treatment. Two children had side effects during treatment: one developed arthritis of the ankle; the other had liver toxicity, whose relationship with moxifloxacin could not be ruled out. We did not observe any case of QT prolongation, central nervous system disorders, growth defects or gastrointestinal disturbances. CONCLUSIONS: A moxifloxacin-containing regimen might be considered for the treatment of TB in children, especially for drug-resistant and extensive forms. However, vigilance for possible side effects is recommended, especially if other drugs are concomitantly used. Studies on wider populations are needed to better define the impact of long-term treatments with quinolones on children's growth and psychomotor development and to outline regulatory indications on moxifloxacin use in the pediatric setting.
OBJECTIVE: To report our experience on the safety and tolerability of moxifloxacin for treating children affected by pulmonary TB. STUDY DESIGN:Children receiving a moxifloxacin-containing anti-TB regimen were included in the study. Their medical records were revised at the end of follow-up. METHODS: We describe nine children treated with moxifloxacin for pulmonary TB at Regina Margherita Children's Hospital (Turin, Italy) between 2007 and 2012. Moxifloxacin was administered orally at 10 mg/kg/day once daily (maximum dose = 400 mg/day) following World Health Organization indications. During treatment, patients were systematically assessed for the development of side effects. RESULTS: Eight children were considered cured at the end of treatment; one child was lost to follow-up after 3 months of treatment. Two children had side effects during treatment: one developed arthritis of the ankle; the other had liver toxicity, whose relationship with moxifloxacin could not be ruled out. We did not observe any case of QT prolongation, central nervous system disorders, growth defects or gastrointestinal disturbances. CONCLUSIONS: A moxifloxacin-containing regimen might be considered for the treatment of TB in children, especially for drug-resistant and extensive forms. However, vigilance for possible side effects is recommended, especially if other drugs are concomitantly used. Studies on wider populations are needed to better define the impact of long-term treatments with quinolones on children's growth and psychomotor development and to outline regulatory indications on moxifloxacin use in the pediatric setting.
Authors: Stephanie Thee; Anthony J Garcia-Prats; Heather R Draper; Helen M McIlleron; Lubbe Wiesner; Sandra Castel; H Simon Schaaf; Anneke C Hesseling Journal: Clin Infect Dis Date: 2014-10-30 Impact factor: 9.079
Authors: Rachel G Greenberg; Cornelia B Landersdorfer; Nazario Rivera-Chaparro; Melissa Harward; Thomas Conrad; Aya Nakamura; Carl M Kirkpatrick; Kenan Gu; Varduhi Ghazaryhan; Blaire Osborn; Emmanuel B Walter Journal: Paediatr Drugs Date: 2022-03-14 Impact factor: 3.022
Authors: F Mignone; L R Codecasa; C Scolfaro; I Raffaldi; L Lancella; M Ferrarese; S Garazzino; C Marabotto; S Esposito; C Gabiano; R Lipreri; P-A Tovo Journal: Epidemiol Infect Date: 2013-12-19 Impact factor: 4.434
Authors: Verena Gotta; Zhiyi Yu; Frank Cools; Karel van Ammel; David J Gallacher; Sandra A G Visser; Frederick Sannajust; Pierre Morissette; Meindert Danhof; Piet H van der Graaf Journal: Pharmacol Res Perspect Date: 2016-11-17
Authors: Mohammed Alsuhaibani; Ghada Felimban; Mohamed Shoukri; Abdullah Alosaimi; Abdullah Almohaizeie; Sami AlHajjar Journal: Int J Pediatr Adolesc Med Date: 2019-01-19